{
    "ticker": "ANEB",
    "name": "Anebulo Pharmaceuticals, Inc.",
    "description": "Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of acute cannabinoid overdose and other related conditions. Founded in 2020, Anebulo is dedicated to addressing the growing public health crisis associated with cannabinoid use. The company's lead product candidate, ANEB-001, is being developed as a potential treatment for cannabinoid overdose, which can lead to significant health issues including anxiety, tachycardia, and psychosis. Anebulo employs a science-driven approach to drug development, leveraging extensive research and clinical insights to bring effective solutions to market. The company's commitment to patient safety and efficacy drives its research initiatives, ensuring that its products meet stringent regulatory standards. Anebulo aims to provide healthcare professionals with reliable treatment options while enhancing the quality of care for patients experiencing acute cannabinoid-related adverse effects. As the landscape of cannabinoid use evolves, Anebulo is poised to play a crucial role in advancing therapeutic options and improving patient outcomes in this emerging field.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Austin, Texas, USA",
    "founded": "2020",
    "website": "https://www.anebulo.com",
    "ceo": "Daniel Cohen",
    "social_media": {
        "twitter": "https://twitter.com/AnebuloPharma",
        "linkedin": "https://www.linkedin.com/company/anebulo-pharmaceuticals"
    },
    "investor_relations": "https://investors.anebulo.com",
    "key_executives": [
        {
            "name": "Daniel Cohen",
            "position": "CEO"
        },
        {
            "name": "David H. Reimann",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ANEB-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Anebulo Pharmaceuticals, Inc. | Therapeutics for Cannabinoid Overdose",
        "meta_description": "Explore Anebulo Pharmaceuticals, Inc., a leader in developing therapies for acute cannabinoid overdose. Discover our innovative product pipeline and commitment to patient care.",
        "keywords": [
            "Anebulo Pharmaceuticals",
            "Cannabinoid Overdose",
            "Biotech",
            "Pharmaceuticals",
            "ANEB-001"
        ]
    },
    "faq": [
        {
            "question": "What is Anebulo Pharmaceuticals focused on?",
            "answer": "Anebulo Pharmaceuticals is focused on developing therapies for acute cannabinoid overdose and related conditions."
        },
        {
            "question": "Who is the CEO of Anebulo Pharmaceuticals?",
            "answer": "Daniel Cohen is the CEO of Anebulo Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Anebulo Pharmaceuticals headquartered?",
            "answer": "Anebulo Pharmaceuticals is headquartered in Austin, Texas, USA."
        },
        {
            "question": "What is Anebulo's lead product candidate?",
            "answer": "Anebulo's lead product candidate is ANEB-001, aimed at treating cannabinoid overdose."
        },
        {
            "question": "When was Anebulo Pharmaceuticals founded?",
            "answer": "Anebulo Pharmaceuticals was founded in 2020."
        }
    ],
    "competitors": [
        "MNKD",
        "CBAY",
        "RGLS",
        "INFI"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}